OncoMatch/Clinical Trials/NCT07297173
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Is NCT07297173 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HLA-mismatched GPBMC infusion for relapsed leukemia.
Treatment: HLA-mismatched GPBMC infusion — This is a Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of chemotherapy combining with HLA-mismatched G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion as a bridging therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed and refractory (R/R) leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Demographics
Lab requirements
Kidney function
serum creatinine <= 2 × ULN or CrCl >= 40 mL/min
Liver function
ALT and AST <= 3 × ULN, total bilirubin <= 1.5 × ULN
Cardiac function
LVEF > 50% by echocardiogram; no significant cardiovascular disease (uncontrolled/highly symptomatic arrhythmias, CHF, MI within 6 months, NYHA class 3 or 4)
Adequate hepatic function including alanine transaminase (ALT) and aspartate aminotransferase (AST )<= 3 × upper limit of normal(ULN), and total bilirubin <= 1.5 × ULN. Adequate renal function including serum creatinine <= 2 × ULN or CrCl>= 40mL/min. LVEF measured by echocardiogram is within the normal range (LVEF > 50%). Cardiovascular disease with clinical significance, such as uncontrolled or highly symptomatic cardiac arrhythmias, congestive heart failure, or myocardial infarction within 6 months prior to screening, or New York Heart Association (NYHA) function class 3 (moderate) or class 4 (severe) heart disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07297173 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify